Tags

Phase III gastric trial

Antengene doses first patient in pivotal Phase III gastric trial

Antengene doses first patient in pivotal Phase III gastric trial

September 22, 2026 | 22:14
Biotechnology company Antengene Corporation dosed the first patient in its Phase III CLINCH-3 trial evaluating antibody-drug conjugate ATG-022 for treating advanced gastric or gastroesophageal junction adenocarcinoma.

Latest News

Samsung and Solidigm join Global Memory Innovation Forum speaker lineup

Samsung and Solidigm join Global Memory Innovation Forum speaker lineup

Huawei Electric Power BU outlines AI grid strategies at AESIEAP conference

Huawei Electric Power BU outlines AI grid strategies at AESIEAP conference

Convera partners with JustLogin to embed cross-border payroll across Southeast Asia

Convera partners with JustLogin to embed cross-border payroll across Southeast Asia

Specialised Therapeutics expands Incyte partnership to market Opzelura in Australia

Specialised Therapeutics expands Incyte partnership to market Opzelura in Australia

Vietnam Investment Review under the Ministry of Finance

Editor-in-Chief: Pham Van Hoanh

Deputy Editors-in-Chief: Le Trong Minh, Ngo Chi Tung, Nguyen Van Hong

Managing Editor: Nguyen Chi Mai

Advertisement  | Contact us

Based on MasterCMS Ultimate Edition 2026 v2.9
Corporate CEO Talk Biz Link PR Newswire Media OutReach Newswire
Investing M&A Outbound Investment Investing in Haiphong
Your Consultant KPMG PwC Indochine Counsel Vilasia Ansarada
Green Growth Energy Efficiency Rethinking Plastics BASF
Property Green Buildings Industrial Properties
Money Insurance Smart Payment Trends Stock Monitor
Infographics
Timeout Travel Hotels & Restaurants The Insider Entertainment Lifestyle
Sports
Photos
Society Swing for the Kids CSR
World News
virs-publications-vir
timeout-vn
ptbv2020